

### REMARKS

Claims 3 and 33-36 are allowed.

Amendments are fully supported by the original disclosure and, thus, no new matter is added by their entry. Substitute paper and computer readable forms of the Sequence Listing are being submitted herewith in response to the Examiner's requirement. The paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same.

The Examiner objected to a difference between the amino acid sequences in Fig. 5 and SEQ ID NO: 4. The amino acid sequence in original SEQ ID NO: 4 is correct as shown by translating the nucleotide sequence of SEQ ID NO: 3. Replacement drawing sheets with a corrected Fig. 5 showing Glu as the last residue are submitted herewith.

The brief description of Fig. 5 is amended to indicate the human and mouse TICAM-1 amino acid sequences are shown as SEQ ID NOS: 2 and 4, respectively. Further, the brief description of Fig. 6 is amended to indicate the portions of SEQ ID NOS: 2 and 4 shown as TICAM-1(TIR).hu and TICAM-1(TIR).mu in the drawing.

The amino acid sequences for Mal(TIR).hu and MyD88(TIR).hu shown in Fig. 6 are added to the Sequence Listing as SEQ ID NOS: 11 and 12, respectively. The brief description of Fig. 6 is amended accordingly.

The brief description of Fig. 16 is amended to indicate the TICAM-1 Sense and Anti-Sense ribonucleotide sequences are shown as SEQ ID NO: 5 and 6, respectively.

Applicants earnestly solicit an early Notice of Allowance. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:                     /Gary R. Tanigawa/                      
Gary R. Tanigawa  
Reg. No. 43,180

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100